Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

The US FDA has cleared the first-in-class tyrosine kinase 2 (Tyk2) inhibitor as Sotyktu, and BMS says it now plans to launch the new drug later this month, aiming to mount a challenge to Amgen's $ ...

On average, Camzyos treatment reduced LVEF by around 4% from a mean starting level of 74% in EXPLORER-HCM, said BMS, which has developed a risk evaluation and mitigation strategy (REMS ...

The Big Pharma companies made a last-ditch effort asking a U.S. appeals court to reconsider their lawsuits against the ...

SlurryKat dealer Bailey Machinery Sales (BMS) will attend next week's FTMTA Farm Machinery Show where it will debut SlurryKat ...

Approved in March 2019, esketamine is currently indicated for use alongside an oral antidepressant for treatment-resistant ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Q3 2024 Earnings Call Transcript November 6, 2024 Evotec SE misses on earnings expectations. Reported EPS is $-0.12 EPS, ...